An interventional study of Rehumanized Intervention and Control Intervention in Rehumanization Intervention and Control Intervention, sponsored by Florida State University. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Florida State University · Not applicable, Interventional, and Treatment
PI (Morgan Robison) left to complete clinical internship
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 350 studies in Suicidal Ideation with a site in United States — 110 open to participants now, 123 under way, 4 of them phase 3. Suicidal Ideation · United States.
Among the 350 studies in Suicidal Ideation with a site in United States, this one is the 305th largest by enrollment of the 321 interventional ones that give a count, is one of 38 that started in 2026, is one of 255 with no phase, and was the 289th registered.
570 studies on the registry are indexed under Suicidal Ideation; 204 are open to participants now.
Browse Suicidal Ideation studies →110 of the 350 studies in Suicidal Ideation with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 12–80
Baylor College of Medicine · Sites in United States
Ages 18–64
Ohio State University · Sites in United States
Ages 18+
University of Michigan · Sites in United States
Ages 18+ · Women only
University of California, San Diego · Sites in United States
Ages 12–30
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 135 Suicidal Ideation studies recruiting now, 52 (39%) set no upper age limit and 79 (59%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
350 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 27 · Phase 3 18 · Phase 4 16
First in 2004; this study’s year is marked. 38 started in 2026.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 66 across the 321 interventional studies, 133 across the 29 observational. Of the 198 that completed or were terminated, 82 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 350 have an industry lead sponsor. The 10 most frequent:
Florida State University is the lead sponsor of 249 studies on the registry; 47 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
Florida State University has 6 studies filed under Suicidal Ideation — fewer than ten, so there is no comparison to draw.
54 of the studies in Suicidal Ideation with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05696691Phase 3The University of Texas Health Science Center at San AntonioKetamine & Crisis Response Plan for Suicidal Ideation in the ED | 2026-12-31 |
| NCT07170657University of Texas Southwestern Medical CenterTeen Recovery Through Inspiration, Support, and Empowerment | 2026-11 |
| NCT06285708Ohio State UniversityEnhancing the Effectiveness of Prolonged Exposure Among Suicidal Individuals With PTSD | 2026-12 |
| NCT05793541Massachusetts General HospitalJust-in-time Interventions for Reducing Short-term Suicide Risk | 2026-12 |
| NCT06701006University of WashingtonIntegrated Suicide Supports and Safety Planning for Youth | 2026-12-01 |
Add all 54 to your calendar (.ics) → With an account.
Among the 350 studies in Suicidal Ideation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this experiment is to further determine if self-dehumanization is a novel risk factor for suicide. This study will reduce self-dehumanization using a novel re-humanization condition and compare this group to a control group to analyze the pathway between higher perceptions of self-dehumanization, suicidal ideation, and changes in oxytocin concentrations.
It is hypothesized that participants randomly assigned to the re-humanized condition will exhibit decreases in suicidal ideation and increases in oxytocin concentrations as compared to the control condition, which will not display significant changes. Further, we will explore if the magnitude of the oxytocin response will partially mediate the change in suicidal ideation.
Purpose: Humans are inherently social beings, and the need for belonging and connection is fundamental. Severe perceptions of social exclusion, non-belonging, and isolation can result in significant psychological harm, including suicide, which claims nearly 50,000 lives annually in the U.S. and affects over 13 million individuals through suicidal ideation (SI). A key predictor of SI, thwarted belongingness, arises from feelings of exclusion and non-belonging, yet more specificity is needed to identify the types of non-belonging that contribute most to suicide risk. Self-dehumanization-a perception of oneself as less than human-emerges as a promising factor in understanding and mitigating SI, with empirical evidence linking it to anxiety, depression, suicidal ideation, and social withdrawal. Preliminary research suggests that self-dehumanization is influenced by neurobiological processes, particularly oxytocin, a hormone critical to social connectedness and self-perception. Low oxytocin levels have been linked to self-dehumanization, reduced social reengagement, and heightened suicide risk, highlighting its potential as a target for intervention. Building on these insights, this study will experimentally induce and reduce self-dehumanization to examine its effects on SI and oxytocin levels. Thus, this study will use a self-dehumanization induction to analyze its impact on SI and oxytocin. Findings will provide a novel framework for integrating psychotherapeutic and neurobiological strategies into suicide prevention efforts.
Research Design/Method: The present study will utilize an experimental design with two groups, an experimental re-humanized group and a comparison control group.
Procedure: All interested participants will be instructed to fill out the screening survey to determine fit. Eligible participants will be invited to complete the study visit in person. Following consent, participants will complete a pre-induction fasted blood draw of 5 milliliters (i.e., approximately a tablespoon of blood). Next, participants will complete the Self-Injurious Thoughts and Behaviors-Short Form interview with the experimenter and a battery of randomized self-report assessments. After completion, eligible participants will then be randomly categorized into the re-humanization intervention or the control intervention. Following this, they will undergo a post-intervention 5 milliliter fasted blood draw. They will then complete a post-induction battery of self-report measures (see Materials). Participants will be queried for any changes in suicide risk and any current suicidal ideation and intent and will receive appropriate interventions (e.g., means safety counseling, safety planning). Upon completion participants will be compensated and provided mental health resources (e.g., the National Suicide Prevention Lifeline). Participants will be contacted one month later to fill out a brief battery of self-report measures. The appointment is expected to take approximately 2 hours to complete.
Data Analyses: All results will be analyzed in R. First, descriptive statistics and zero-order bivariate correlation analyses will be assessed. For this study, repeated measures analysis of covariance (ANCOVAs) will be used to examine group differences (i.e., the active re-humanized condition and control condition) in changes in oxytocin levels, self-dehumanization scores, and suicidal ideation, controlling for social isolation (i.e., thwarted belongingness, a factor of the Interpersonal Needs Questionnaire). Post-hoc pairwise comparisons will be conducted if the omnibus test indicates statistically significant effects. Following this, exploratory analyses will be conducted to assess if oxytocin partially mediates the relationship between self-dehumanization pre-experimental manipulation and suicide risk post-experimental manipulation (controlling for suicide risk at pre-experimental manipulation) through bootstrapped mediation procedures (i.e., 10,000 samples using the mediation and lavaan packages in R).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This self-rehumanization intervention will involve a set of multi-sensory activities (i.e., reading, writing, and speaking) to prompt body and soul awareness, agency, connection, and creativity.
Other: Rehumanized Intervention · Diagnostic Test: Clinical Interview · Other: Self-Report Measures · Other: Blood Draw
Control Intervention about political attitudes
Other: Control Intervention · Diagnostic Test: Clinical Interview · Other: Self-Report Measures · Other: Blood Draw
Participants will: 1\. be provided with a lay summary of an ostensible research article that used quantitative and qualitative data to capture the experiences of feeling "less than human" and mechanisms for reclaiming human identity. The summary will reveal general themes of humanness based on participant responses including body and soul awareness, agency, connection, and creativity. 1. write a 30-minute reflective essay on "how did the rehumanization efforts described in the survey make people feel more human?" where they will be encouraged to use examples from their own lives 2. asked to create videos based on the insights shared in the essays. The researchers will explain, "We would like to record you reading your essay on camera. We believe it would be especially impactful for clinicians developing these interventions to hear directly from someone who has recently navigated similar experiences."
Participants will: 1\. be provided with a lay summary of an ostensible research article that used quantitative and qualitative data to capture the experiences of political attitudes and routes to political sophistication. The summary will reveal general themes of political sophistication based on participant responses including gathering information through diverse news outlets, analyzing policy and legislation, and participation in civic engagement 1. write a 30-minute reflective essay on ""how did the political efforts described in the survey refine political attitudes?" where they will be encouraged to use examples from their own lives 2. asked to create videos based on the insights shared in the essays. The researchers will explain, "We plan to take excerpts of what you write here and share it with future voters to aid in developing political attitudes."
Self-Injurious Thoughts and Behaviors Interview-Short Form (SITBI-SF). Participants will complete an in-person interview featuring 72-items about their history of self-injury and suicidal behaviors. This interview includes 6 yes/no style questions about suicidal thoughts, suicidal plans, suicidal gestures, suicidal attempts, nonsuicidal self-injury thoughts, and nonsuicidal self-injury. Each category that is endorsed, across the lifetime, has follow up questions surrounding times, duration, intensity, severity, type, and if medical attention was sought. This interview has sound psychometric properties.
Depressive Symptom Index - Suicidality Subscale (DSI-SS). Patient Health Questionnaire-8 (PHQ-8). Interpersonal Needs Questionnaire (INQ). Self-Dehumanization Scale (SDS).
Five milliliters of blood will be drawn before and after study interventions for the quantification of plasma oxytocin concentrations by certified phlebotomists. Samples will be collected into chilled EDTA tubes, inverted ten times to mix with anticoagulants, and centrifuged at 1600g for 15 minutes at 4˚C. Cleared plasma will be aliquoted into cryotubes and stored at -80˚C. Consistent with expert recommendations, oxytocin levels will be obtained from the samples diluted 1:4 (i.e., oxytocin can be discarded through plasma proteins when incorporating an extraction step before conducting the enzyme-linked immunosorbent assay \[ELISA\]). Second, to buffer against contrasting concerns, an aliquot of each sample will be analyzed for test-retest purposes. Oxytocin concentrations will be measured using a validated commercially available and sensitive ELISA neurophysin kit (Abcam).
Change in Suicidal Ideation
Suicidal Ideation will be measured using the Depressive Symptom Index-Suicidality Subscale (DSI-SS) where the scores range from 0-12 and higher scores indicate higher levels of suicidal ideation. These analyses will control for Baseline suicidal ideation and the thwarted belongingness sub-scale from the Interpersonal Needs Questionnaire where thwarted belongingness scores range from 1-56 and higher scores indicate greater perceptions of thwarted belongingness.
Time frame: This measure will be collected at Baseline and after the experiment (approximately 30 minutes later). Then, suicidal ideation will be collected again 1 month later.
Change in Oxytocin Levels
Five milliliters of blood will be drawn before and after study interventions for the quantification of plasma oxytocin concentrations by certified phlebotomists (including the PI, who is already certified and currently collecting samples for a T-32 supported project). Samples will be collected into chilled EDTA tubes, inverted ten times to mix with anticoagulants, and centrifuged at 1600g for 15 minutes at 4˚C. Cleared plasma will be aliquoted into cryotubes and stored at -80˚C. Consistent with expert recommendations, oxytocin levels will be obtained from the samples diluted 1:4 (i.e., oxytocin can be discarded through plasma proteins when incorporating an extraction step before conducting the enzyme-linked immunosorbent assay \[ELISA\]). Second, to buffer against contrasting concerns, an aliquot of each sample will be analyzed for test-retest purposes. Oxytocin concentrations will be measured using a validated commercially available and sensitive ELISA neurophysin kit (Abcam).
Time frame: This measure will be collected at Baseline and after the experiment (approximately 30 minutes later).
Plan to share: Undecided — IPD de-identified demographic, self-report, and neurobiological (i.e., oxytocin) data may be shared. Data will not be shared if the participant denies to share their data. Data will be accessible by contacting the Central Contact Person of the study: Morgan Robison (mrobison@psy.fsu.edu). If data are uploaded to a public repository, the external link will be made available here.
Start is estimated for Aug 2026; primary completion for Aug 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
PI (Morgan Robison) left to complete clinical internship
PI (Morgan Robison) left to complete clinical internship
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.